Usages et mesusages des benzodiazepines chez les patients souffrant de troubles psychiatriques
dc.rights.license | open | en_US |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | PANES, Arnaud | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | FOURRIER-REGLAT, Annie | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | VERDOUX, Helene
IDREF: 115951903 | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | DAUBECH-TOURNIER, Marie | |
dc.date.accessioned | 2020-12-14T10:33:22Z | |
dc.date.available | 2020-12-14T10:33:22Z | |
dc.date.issued | 2018-10 | |
dc.identifier.issn | 0755-4982 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/21431 | |
dc.description.abstractEn | The psychiatric patients are not only particularly exposed to benzodiazepines; they may also be more vulnerable to their side effects than general population. Benzodiazepines are frequently misused in psychiatric patients in terms of duration, dose and number of concomitant medications. There is no evidence that benzodiazepines are effective against most psychiatric disorders, including depression and suicidal risk. Several studies have shown associations between benzodiazepine use and depression worsening, increased disinhibition, suicide risk, anxiety, aggression, and even mortality in patients with psychiatric disorders. Despite the common use of benzodiazepine drugs by clinicians, large and methodologically sound studies are lacking to document the patterns of benzodiazepine use in populations with psychiatric disorders and their specific risks in these patients. It is not known whether it is legitimate to apply the good practice recommendations for benzodiazepines in patients with severe psychiatric disorders. | |
dc.language.iso | FR | en_US |
dc.subject.en | PharmacoEpi-Drugs | |
dc.title.en | Usages et mesusages des benzodiazepines chez les patients souffrant de troubles psychiatriques | |
dc.title.alternative | Presse Med | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1016/j.lpm.2018.10.003 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 30454581 | en_US |
bordeaux.journal | Presse medicale (Paris, France | en_US |
bordeaux.page | 886-891 | en_US |
bordeaux.volume | 47 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 10 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.team | PharmacoEpi-Drugs | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03063779 | |
hal.version | 1 | |
hal.date.transferred | 2020-12-14T10:33:26Z | |
hal.export | true | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Presse%20medicale%20(Paris,%20France&rft.date=2018-10&rft.volume=47&rft.issue=10&rft.spage=886-891&rft.epage=886-891&rft.eissn=0755-4982&rft.issn=0755-4982&rft.au=PANES,%20Arnaud&FOURRIER-REGLAT,%20Annie&VERDOUX,%20Helene&DAUBECH-TOURNIER,%20Marie&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |